OPEN Research Support
head

Professor and consultant
Frantz Rom Poulsen
Department of Neurosurgery, Odense University Hospital


Projekt styring
Projekt status    Sampling ongoing
 
Data indsamlingsdatoer
Start 01.05.2018  
Slut 01.05.2020  
 



Twentyfour or 48 hours closed passive subdural drainage after burr hole evacuation of chronic subdural hematoma? A national randomized controlled study

Short summary

Chronic subdural hematoma (CSDH) is a collection of liquefied blood between the dura mater and arachnoid layer of the brain. The incidence of CSDH increases with age and with an ageing population, a rise in CSDH prevalence is anticipated. We have commenced a randomized clinical national multicenter study investigating 24 vs 48 hours of closed passive subdural drainage after burr hole evacuation of chronic subdural hematoma. Our primary endpoint is retreated haematoma within 3 months.


Rationale

BACKGROUND:

Chronic subdural hematoma (CSDH) is a collection of liquefied blood between the dura mater and arachnoid layer of the brain. The incidence of CSDH increases with age and with an ageing population, a rise in CSDH prevalence is anticipated. The Danish National Board of Health has requested treatment guidelines for major diseases including CSDH which was implemented february 1th 2018.  A national standard for CSDH treatment creates an optimal platform for quality control and research. 

INTRODUCTION:

We have commenced a randomized clinical national multicenter study investigating 24 vs 48 hours of closed passive subdural drainage after burr hole evacuation of chronic subdural hematoma. Our primary endpoint is retreated haematoma within 3 months.


Description of the cohort

We include patients with a chronic subdural haematoma (ICD10 S065C) requiring evacuation with placement of a passive subdural drain.

We exclude patients with previous neurosurgery and conditions requiring neurosurgery, age < 60 years, a head traume within 2 weeks, patients who fail to be randomized within 24 hours and patients not able to give inform consent.


Data and biological material

Data will be collected from the patients medical chart and will include gender, age, dates of contact to hospital, symptoms, medical history, paraclinical results during admission, radiological results, type of surgery, death and recurrence of haematoma.


Collaborating researchers and departments

Department of Neurosurgery, Rigshospitalet, Copenhagen

  • Senior Consultant Kåre Fugleholm Buch

Departmen of Neurosurgery, Odense University Hospital

  • Senior Consultant Frantz Rom Poulsen

Department of Neurosurgery, Aarhus University Hospital

  • Senior Consultant Bo Bergholt

Department of Neurosurgery, Aalborg University Hospital

  • Senior Consultant Torben Hundsholt

Department of Neurosurgery, Aalborg University Hospital

  • Senior Consultant Carsten Bjarkam